Buy Rating for Moleculin Biotech: Promising Progress with WP1066 in Pediatric Brain Tumors
TipRanks (Wed, 17-Dec 12:45 PM ET)
Moleculin Biotech Reports Positive Phase 1 Trial Results
TipRanks (Wed, 17-Dec 9:01 AM ET)
Globe Newswire (Wed, 17-Dec 8:31 AM ET)
Moleculin Biotech Regains Nasdaq Compliance
TipRanks (Tue, 16-Dec 5:55 PM ET)
Market Chameleon (Wed, 10-Dec 4:02 AM ET)
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
Globe Newswire (Wed, 10-Dec 8:30 AM ET)
Globe Newswire (Tue, 9-Dec 8:07 AM ET)
Moleculin’s New Annamycin Brain Tumor Collaboration Targets Unmet Needs in Glioblastoma
Market Chameleon (Mon, 8-Dec 3:48 AM ET)
Moleculin Announces New Annamycin Collaboration in Brain Tumors
Globe Newswire (Mon, 8-Dec 8:21 AM ET)
Moleculin to Participate in the Virtual Investor Closing Bell Series
Globe Newswire (Wed, 26-Nov 9:15 AM ET)
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Moleculin Biotech trades on the NASDAQ stock market under the symbol MBRX.
As of December 19, 2025, MBRX stock price climbed to $3.90 with 141,208 million shares trading.
MBRX has a beta of 1.73, meaning it tends to be more sensitive to market movements. MBRX has a correlation of 0.02 to the broad based SPY ETF.
MBRX has a market cap of $8.07 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, MBRX traded as high as $618.75 and as low as $3.63.
The top ETF exchange traded funds that MBRX belongs to (by Net Assets): VXF.
MBRX has underperformed the market in the last year with a price return of -91.4% while the SPY ETF gained +18.1%. MBRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -61.3% and -46.1%, respectively, while the SPY returned +2.8% and -0.5%, respectively.
MBRX support price is $3.38 and resistance is $4.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MBRX shares will trade within this expected range on the day.
